Generation of reactive oxygen metabolites, thromboxane increases, and vasoconstriction have been implicated in the pathogenesis of acute edematous lung injury, such as that seen in patients with the Adult Respiratory Distress Syndrome (ARDS), but their interactions are unknown. We hypothesized that reactive 02 products would stimulate arachidonic acid metabolism in lungs and that vasoactive products of arachidonate, such as the potent vasoconstrictor thromboxane A2, might then mediate 02-metabolite-induced pulmonary vasoconstriction. We found that 02 metabolites generated by injection of purine plus xanthine oxidase caused increases in mean pulmonary artery perfusion pressures (27±4 mmHg) in isolated perfused lungs. In addition, purine plus xanthine oxidase also caused 30-fold increases in perfusate levels ofthromboxane B2 (the stable metabolite ofthromboxane A2) compared with only twofold increases in 6-keto-PGFia (the stable metabolite of prostacyclin). Moreover, prior addition of catalase inhibited both vasoconstriction and the thromboxane B2 production seen in isolated lungs following injection of purine plus xanthine oxidase. Similarly, pretreatment with cyclooxygenase inhibitors, either aspirin or indomethacin, also completely blocked thromboxane generation and markedly attenuated pressor responses usually seen after purine plus xanthine oxidase (increase in mean pulmonary artery perfusion pressures, 4.4±1.5 mmHg).
Introduction
Reactive oxygen metabolites from neutrophils and other sources appear to contribute to the development of acute edematous lung injury, such as that seen in the Adult Respiratory Distress Syndrome (ARDS) and other disorders (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recently, we found that hydrogen peroxide (H202) or H202-derived products caused pulmonary vasoconstriction and permeability pulmonary edema in isolated saline-perfused rabbit lungs (11) . Since 02 metabolites can interact with cell membranes (12) and since cell membrane stimulation is frequently associated with liberation of arachidonic acid from membrane phospholipids (13) , it appeared that intermediate arachidonate-derived factors might be involved in 02-metabolite-induced vasoconstriction or pulmonary edema. Based on this possibility, we hypothesized that 02 metabolites stimulate arachidonate metabolism and that production and release of potent vasoactive arachidonate products, such as thromboxane, might in part mediate oxidant-induced vasoconstriction. This hypothesis was supported by finding that exposure of isolated lungs to 02 metabolites generated by xanthine oxidase caused generation of large amounts of thromboxane and that addition ofcatalase, an H202 scavenger, aspirin or indomethacin, cyclooxygenase inhibitors, or imidazole, a thromboxane synthetase inhibitor, similarly decreased both per-fusate thromboxane increases and elevations of mean perfusion pressures in isolated lungs perfused with 02 metabolites produced by xanthine oxidase.
Methods
Reagents. Xanthine oxidase (grade I, buttermilk), purine (7H-Imidazo [4,5-d] pyrimidine), glucose oxidase (type V, Aspergillus niger), ,8-D (+) glucose, superoxide dismutase (SOD', type I, 2,650 U/mg protein), catalase (bovine liver, 2,000 U/mg protein), acetyl salicylic acid (aspirin), indomethacin, imidazole, bovine serum albumin (BSA, Cohn fraction V), bromcresol green (albumin color reagent), and horse-heart ferricytochrome c were obtained from Sigma Chemical Co., St. Louis, MO. Papaverine hydrochloride was obtained from Eli Lilly and Co., Indianapolis, IN. In some experiments, catalase was further purified by passage through a Sephadex G-100 column, concentrated and desalted by pressure dialysis (Amicon Ultrafiltration System, Diaflo XM 100 membrane, Amicon Corp., Danvers, MA), and lyophilized.
Isolatedperfused lung standardprotocol. New Zealand White rabbits (1.8-2.8 kg) were used for all isolated lung preparations. Each rabbit was anesthetized with xylazine (Rompun, Cutter Laboratories, Shawnee, KS; 10 mg/kg intramuscularly) and ketamine (Ketalar, Parke-Davis & Co., Detroit, MI; 25-50 mg/kg intravenously). A tracheostomy was performed and each rabbit was ventilated with 95% room air:5% CO2 during the operative procedure (Harvard small animal respirator, model 670D, Harvard Apparatus Co., Inc. Minnis, MA; fixed tidal volume, 10-15 cm3/kg, 25 breaths/min; positive end-expiratory pressure, 2 cm H20). A median sternotomy was performed and 500 U heparin (Panheprin, Abbott Laboratories, N. Chicago, IL; 1,000 U/ml) was injected into the right ventricular cavity. Cannulas were then placed in the main pulmonary artery and left ventricular cavity. The perfusate medium was Greenberg-Bohr physiological saline solution (14) containing 3% BSA at 37°C and pH 7.4. The pulmonary circulation was washed with 500 ml of perfusate using a peristaltic pump (perfusate flow rate, 40 cm3/kg body weight per min, Cole-Parmer Instrument Co., Chicago, IL). This washout procedure reduced subsequent recirculating perfusate neutrophil and platelet counts to <3% ofnormal rabbit values. Perfusion was then interrupted for 5 min while the lungs and heart were dissected free and suspended in a humid 37°C chamber from a force-displacement transducer (model FTIO G, Grass Instruments Co., Quincy, MA) that allowed continuous measurement of lung preparation weight changes. Perfusion was then restarted at the same fixed flow rate. The final recirculating volume was 300 ml. The level of the venous outflow line was kept -10 cm below the lung preparation, causing outflow pressure to be .0 mmHg. Mean perfusion pressures were monitored with a pressure transducer (type 4-327-0010, Bell & Howell Co., Pasadena, CA) zeroed at the level ofthe main pulmonary artery cannula. Perfusion pressures initially ranged from 8 to 12 mmHg in all preparations and were followed throughout each experiment (see Results). Each preparation was perfused for 10-20 min prior to experimental manipulations to insure stability. During the base-line period, perfusion pressures and weights in individual preparations varied <3 mmHg and 2 g, respectively. Experimental agents were added to the perfusate reservoir after 10, 20, or 25 min in the following order 02 radical scavenger or arachidonic acid metabolism inhibitor, substrate, and enzyme. Perfusion was continued for an additional 30 min (55 min total) or until gross edema necessitated an earlier termination. In selected experiments, papaverine 1. Abbreviations used in this paper: PGFI,, prostaglandin Fla; SOD, superoxide dismutase. was injected into the perfusate after the addition of purine and xanthine oxidase and was titrated (average final papaverine concentration, 0.1 mg/ml) to maintain nearly constant perfusion pressures. All perfusion pressure data are reported as the maximum pressure increases prior to any lung weight gains.
Measurement of thromboxane B2 and 6-keto-prostaglandin Fl, (PGF,4). Perfusate samples (3 ml) were drawn from the venous outflow line before and after addition of xanthine oxidase. Samples were then immediately mixed with 20 ju1 of 0.4% aspirin in phosphate-buffered saline, pH 7.0. Subsequently, the samples were centrifuged (500 g for 8 min at 4°C) and supernatants were stored at -70°C until assayed. Unextracted samples (0.2 ml) were assayed in duplicate by a doubleantibody radioimmunoassay procedure (15) . The assay sensitivity for thromboxane B2 and 6-keto-PGF,a is 0.005-0.010 ng/tube, with a coefficient of variation for repetitive assays of 10% (15) .
Measurement ofsuperoxide anion (0). Aspirin, indomethacin, or imidazole did not interfere with purine plus xanthine oxidase-induced 02 metabolite production as measured by O-dependent reduction of horse heart ferricytochrome c spectrophotometrically (16) .
Statistics. Data are reported as mean±SEM except where indicated. Comparisons between purine-xanthine oxidase or ,B-D glucose-glucose oxidase-exposed lungs and multiple groups were made by a one-way analysis of variance followed by Scheffe's Multiple Comparison Test (17) . Probability values < 0.05 were considered significant.
Results
Addition ofpurine plus xanthine oxidase to perfusates ofisolated saline-perfused rabbit lungs caused marked increases in lung perfusion pressures that were abolished by preaddition ofcatalase (Fig. 1 ). This observation suggested that H202 or an H202derived product was responsible for vasoconstriction. In contrast, addition of SOD, a scavenger of superoxide anion (02), did not alter purine plus xanthine oxidase-mediated increases in perfusion pressures, suggesting that°2 did not cause these responses (Fig. 1 ). The contention that H202, and not°2, initiated these pressure changes was further supported when glucose oxidase, an enzyme that generates H202 but not O-(6), caused similar increases in lung perfusion pressures that were inhibitable by preaddition of catalase (Fig. 2) .
Addition of purine plus xanthine oxidase also caused 30fold increases in thromboxane B2 levels (the stable metabolite of thromboxane A2, Fig. 3 ) while producing only twofold increases in 6-keto-PGFI. levels (the stable metabolite of prostacyclin, Fig. 4 ) in perfusates of isolated lungs. Specifically, 15 min after addition of purine plus xanthine oxidase, lung perfusates had thromboxane B2 and 6-keto-PGFI. levels of 0.43±0.19 and 0.76±1.5 ng/ml (mean±SD) compared with 0.02±0.02 and 0.37±0.10 ng/ml at the start ofthe experiments. The rate of thromboxane generation was approximately linear during the first 30 min after addition of xanthine oxidase. Addition ofcatalase or SOD inhibited punne plus xanthine oxidasemediated rises in thromboxane B2 levels (Fig. 3 ). Catalase, but not SOD, inhibited the purine plus xanthine oxidase-induced increases in 6-keto-PGFia levels (Fig. 4 ).
Having observed this apparent stimulation of arachidonate metabolism by xanthine oxidase-derived 02 metabolites, we next examined whether thromboxane generation contributed to Figure 3 . Purine (2 mM) plus xanthine oxidase (0.02 U/ml) caused 30-fold increases in thromboxane B2 levels in isolated lung perfusates. Thromboxane B2 is expressed as percent base-line value (thromboxane B2 value at 15 min after purine plus xanthine oxidase divided by thromboxane B2 value at 15 min before xanthine oxidase x 100). Superoxide dismutase (100 ,ug/ml, n = 4; 10 gg/ml, n = 1; 1 ,ug/ml, n = 1) or catalase (100 ,ug/ml) inhibited xanthine oxidase-induced increases in thromboxane B2. Each symbol represents one experiment. Asterisk indicates significant difference (P < 0.05) from purine plus xanthine oxidase group. were inhibited by preaddition of either of two cyclooxygenase inhibitors, aspirin or indomethacin (Fig. 5 ). Addition of aspirin or indomethacin also abolished increases in thromboxane B2 and 6-keto-PGFIa levels. Furthermore, imidazole, a thromboxane synthetase inhibitor (18) , also attenuated purine plus xanthine oxidase-induced pressor responses (Fig. 6 ). At the higher dose (7.3 mM), imidazole decreased production of thromboxane B2 but increased 6-keto-PGFIa production (6-keto-PGFIa levels increased 3.7-fold). Thus, concentrations of imidazole required to inhibit thromboxane synthetase in our system did not adversely affect cyclooxygenase activity. Additional control experiments demonstrated that aspirin, indomethacin, and imidazole had no effect on the generation ofOby xanthine oxidase in vitro as evidenced by their noninterference in a standard cytochrome c reduction assay. Also, addition of catalase, SOD, imidazole, aspirin, or indomethacin alone did not affect baseline perfusion pressures in any experiment (data not shown). Finally, we examined if thromboxane generation may have been a consequence of O2-metabolite-induced vasoconstriction. Injection of the vasodilator, papaverine, attenuated xanthine oxidase-induced pressor responses by 80% (increase in mean perfusion pressures, 4.7±0.6 mmHg, n = 3), but did not affect the increase in thromboxane levels (4,016±2,405, percent base line). This finding suggested that exposure to 02 metabolites caused thromboxane generation independently of vasoconstric- tion.
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Discussion
This investigation shows that xanthine oxidase-derived 02 metabolites can stimulate the generation ofthromboxane in isolated Imidazole was examined for any nonspecific vasodilator activity. Imidazole alone did not affect base-line perfusion pressures. Furthermore, imidazole did not affect potassium chloride-induced vasoconstriction (n = 3). Each symbol represents one experiment. Asterisk indicates significant difference (P < 0.05) from purine plus xanthine oxidase group.
saline-perfused rabbit lungs. Furthermore, 02 metabolite-induced thromboxane generation appears to be an important mechanism responsible for oxidant-induced vasoconstriction. Considerable evidence suggests that oxygen metabolites could cause thromboxane generation by interacting at several sites in the pathways ofarachidonic acid metabolism (19) (20) (21) (22) (23) (24) . Our finding that cyclooxygenase inhibitors effectively blocked xanthine oxidase-induced thromboxane generation suggested that xanthine oxidase-derived 02 metabolites were affecting the initial steps of arachidonate metabolism, including arachidonic acid release from phospholipids or cyclooxygenase enzyme activity. The enormous increase in thromboxane levels in our system indicates that 02 metabolites most likely caused increased liberation of substrate arachidonic acid from cell membranes in some fashion. Two major possibilities seem to exist. It is known that 02 metabolites can attack unsaturated bonds of membrane lipids ( 12) , and that this process oflipid peroxidation can become autocatalytic and lead to changes in membrane structure that allow for increased release ofmembrane-bound arachidonic acid. Indeed, cell membrane alterations often result in release of arachidonic acid or its products (13) . Another possibility would be stimulation of phospholipases by 02 metabolites. The latter is an attractive mechanism which has not been described. 02 metabolites might also directly stimulate cyclooxygenase. Indeed, various peroxides can accelerate cyclooxygenase activity (25, 26) . Although our investigation did not attempt to determine which of these several possibilities was most important for 02metabolite-induced thromboxane generation, we consider the direct perturbation of cell membranes by 02 metabolites to be 611 02 Metabolites Stimulate Thromboxane Production 51 3H 36 F m + _ S * * the most likely mechanism leading to production ofarachidonate metabolites in this system. Another issue raised by our findings is the cellular site of production of arachidonate metabolites seen in isolated lungs exposed to 02 metabolites. Since most mammalian cells have the metabolic capability of generating arachidonate products (13, 27) , it is probable that resident lung cells, such as endothelial cells or fibroblasts, contribute to the thromboxane and prostacyclin generation. In contrast, it is less probable that circulating blood cells contribute. For example, it is unlikely that platelets are the source of thromboxane in this model. The isolated lung vasculature is thoroughly washed prior to the beginning of each experiment. As a result of this washing procedure, circulating platelets are not detectable in the perfusing saline solution. Furthermore, lung sections prepared for light and electron microscopy reveal very few residual platelets. Another possibility is that neutrophils contribute to thromboxane generation. However, while some neutrophils are apparent in lung histologic sections, the numbers ofcirculating neutrophils are so markedly decreased in isolated lung perfusates that it seems only remotely possible that they are the major source of thromboxane.
A relationship between 02-metabolite-induced thromboxane generation and vasoconstriction seems likely. Thromboxane is a well-recognized, potent vasoconstrictor. Moreover, addition ofcatalase completely inhibited purine-xanthine oxidase-induced thromboxane generation and no vasoconstriction occurred. Furthermore, aspirin, indomethacin, or imidazole inhibited purine-xanthine oxidase-induced vasoconstriction and thromboxane generation without affecting oxygen radical generation. These results suggest that thromboxane was a mediator of oxidantinduced vasoconstriction. However, other findings in our study suggest that thromboxane may not be the only vasoconstrictor in this model. For example, SOD significantly reduces thromboxane generation; yet, a pressor response still occurs. However, as shown in Fig. 3 , the amount of thromboxane generated in the presence of SOD is greater than in the isolated lungs with no additions. It may be that thromboxane generation must be almost totally suppressed to prevent 02-metabolite-induced vasoconstriction. A second concern regarding the potential contribution of mediators other than thromboxane is that a strict correlation does not exist between the amount of thromboxane generated and the intensity of vasoconstriction. This does not mean that thromboxane is not involved but rather suggests that 02-metabolite-induced vasoconstriction potentially involves more than one vasoactive substance. For instance, even when aspirin or indomethacin totally inhibited the rise in thromboxane levels, a small pressor response remained (4.4±1.5 mmHg, Fig.  5 ), suggesting that a vasoactive substance in addition to thromboxane was present in the system. A possible explanation for the small pressor response seen in the presence ofcyclooxygenase inhibitors would be that arachidonic acid was shunted away from the cyclooxygenase pathway into the lipoxygenase pathway. This effect has been shown to exist in platelets where aspirin decreased cyclooxygenase products while simultaneously increasing lipoxygenase products (28). If this phenomenon oc-curred in our system, the aforementioned residual pressor response seen in the presence of cyclooxygenase inhibitors may have been caused by a vasoconstricting lipoxygenase product (29) . Additional factors that might account for the lack of a strict correlation between thromboxane levels and the degree of vasoconstriction are variabilities in (a) the reactivity of pulmonary vascular beds between rabbits, (b) the responsiveness of individual rabbits to thromboxane, prostacycin, and/or other factors, and (c) factors that affect the binding of thromboxane to its receptor. These variables cannot be readily measured in our system. To summarize, it is clear that arachidonate metabolites are generated in response to 02 metabolites in this model. Furthermore, it appears that although thromboxane very likely mediates a major part of 02-metabolite-induced vasoconstriction, other factors which stimulate vasoconstriction may also be involved.
The finding that low-dose imidazole (3.7 mM, Fig. 6 ) reduced thromboxane levels without significantly reducing purine-xanthine oxidase-induced vasoconstriction raised the possibility that imidazole was effective at the higher dose (7.3 mM) by acting as a nonspecific vasodilator in addition to a thromboxane synthetase inhibitor. We are not aware of imidazole being reported as a nonspecific vasodilator. As noted in Fig. 6 , imidazole had no vasodilator effect either on base-line perfusion pressures or on potassium chloride-induced vasoconstriction. Thus, it may well be that thromboxane generation must be almost totally suppressed by the higher dose of imidazole to prevent 02-metabolite-induced vasoconstriction. Similarly, we were not able to demonstrate any nonspecific vasodilating effect of catalase. Furthermore, we are not aware that such an effect of catalase has been described.
Thromboxane-dependent pulmonary vasoconstriction has been demonstrated in several models. Infusion of endotoxin into dogs or sheep raises pulmonary vascular resistances (30-34). This effect apparently involves arachidonate products since the resulting pulmonary vasoconstriction can be blocked by cyclooxygenase inhibitors (35) . Furthermore, the rise in pulmonary vascular resistance is associated with increased thromboxane B2 levels in sheep lung lymph (36) (37) (38) . Thromboxane also appears to be the important mediator in a model ofactivated platelet-induced pulmonary hypertension (39) . Our studies demonstrate that exposure to 02 metabolites may be another mechanism that could stimulate the production of vasoactive arachidonate products within the lung and result in pulmonary hypertension.
